Home » Healthcare » Pharmaceuticals » Subcutaneous Immunoglobulin (SCIg) Market

Subcutaneous Immunoglobulin (SCIg) Market By Concentration (10%, 16.5%, 20%, Others); By Application (Primary Immunodeficiency Diseases (PID), Secondary Immunodeficiency Diseases (SID), Neurological Disorders (e.g., CIDP), Others); By End-User (Hospitals, Homecare Settings, Clinics / Specialty Clinics) – Growth, Share, Opportunities & Competitive Analysis, 2024 – 2032

Name: Subcutaneous Immunoglobulin (SCIg) Market - Demand, Size and Competitive Analysis
Creator: Credence Research Inc.
Published: 2025-06-28
License: https://www.credenceresearch.com/info/privacy-policy
Keywords: Subcutaneous Immunoglobulin (SCIg) Market

Summary
Table Of Content
Request Sample

REPORT ATTRIBUTE	DETAILS
Historical Period	2020-2023
Base Year	2024
Forecast Period	2025-2032
Subcutaneous Immunoglobulin (SCIg) Market Size 2024	USD 5,600.0 million
Subcutaneous Immunoglobulin (SCIg) Market, CAGR	8.70%
Subcutaneous Immunoglobulin (SCIg) Market Size 2032	USD 10,915.0 million

Market Overview

The Subcutaneous Immunoglobulin (SCIg) market size was valued at USD 3,568.4 million in 2018, increased to USD 5,600.0 million in 2024, and is anticipated to reach USD 10,915.0 million by 2032, growing at a CAGR of 8.70% during the forecast period.

The Subcutaneous Immunoglobulin (SCIg) market is led by prominent players such as CSL Behring, Takeda Pharmaceutical Company Limited, Grifols, S.A., and Octapharma AG, which collectively hold a significant share of the global market. These companies dominate through broad product portfolios, advanced manufacturing capabilities, and strong global distribution channels. Emerging players like Bharat Serums and Vaccines Ltd (BSV) and ADMA Biologics are also gaining regional traction with competitive pricing and niche offerings. North America leads the global SCIg market with approximately 48% market share in 2024, driven by high disease awareness, advanced healthcare infrastructure, and increasing preference for home-based therapies.

Market Insights

The Subcutaneous Immunoglobulin (SCIg) market was valued at USD 5,600.0 million in 2024 and is projected to reach USD 10,915.0 million by 2032, growing at a CAGR of 8.70% during the forecast period.
Increasing prevalence of primary and secondary immunodeficiency diseases, coupled with growing patient preference for home-based therapies, is significantly driving the demand for SCIg treatments globally.
The market is witnessing a strong trend toward high-concentration products, particularly the 20% segment, which holds the largest share due to reduced infusion times and improved patient comfort.
The competitive landscape is dominated by key players such as CSL Behring, Takeda Pharmaceutical Company Limited, Grifols, S.A., and Octapharma AG, with companies focusing on innovation, partnerships, and expansion strategies to strengthen their market positions.
North America leads the global market with a 48% share in 2024, followed by Europe with 30%, while Asia Pacific is the fastest-growing region with a CAGR of 10.8%.

Access crucial information at unmatched prices!

Request your sample report today & start making informed decisions powered by Credence Research Inc.!

Download Sample

Market Segmentation Analysis:

By Concentration:

In the Subcutaneous Immunoglobulin (SCIg) market, the 20% concentration segment holds the largest market share, driven by its higher efficiency, lower infusion time, and patient preference for reduced administration frequency. This concentration offers significant benefits in terms of treatment convenience and improved patient adherence, especially in homecare settings. Additionally, its higher immunoglobulin content enables faster therapeutic outcomes, making it the preferred choice among healthcare providers. The growing shift towards patient-centric therapies and the increasing adoption of home-based treatments continue to support the dominance of the 20% concentration segment in the market.

For instance, CSL Behring’s Hizentra supports infusion volumes up to 25 mL per site at flow rates of 35 mL/hour per site after tolerance builds through multiple sessions.

By Application:

The Primary Immunodeficiency Diseases (PID) segment dominates the Subcutaneous Immunoglobulin (SCIg) market, holding the largest share due to the rising prevalence of genetic immunodeficiency disorders and the need for lifelong immunoglobulin replacement therapy. Patients with PID require regular infusions to prevent recurrent infections, making SCIg an essential treatment option. The segment’s growth is further fueled by increasing awareness, improved diagnostic rates, and advancements in immunoglobulin therapies. Moreover, the flexibility and safety of SCIg administration in homecare settings make it a preferred treatment modality for PID, reinforcing the segment’s leading position.

For instance, Takeda’s Cuvitru enables infusion volumes of 60 mL per site delivered at 60 mL/hour per site, allowing many PID patients to complete therapy within one hour.

By End-User:

Homecare settings represent the dominant end-user segment in the Subcutaneous Immunoglobulin (SCIg) market, accounting for the largest market share. The increasing patient inclination towards self-administration, coupled with the convenience and reduced healthcare costs associated with home-based treatments, significantly drives this segment’s growth. Patients and caregivers prefer homecare due to its flexibility, minimized hospital visits, and lower risk of hospital-acquired infections. Additionally, advancements in infusion devices and supportive healthcare policies further encourage the adoption of SCIg therapies in home settings, solidifying this segment’s leadership in the market.

Market Overview

Increasing Prevalence of Immunodeficiency Disorders

The rising global prevalence of primary and secondary immunodeficiency diseases is a significant growth driver for the SCIg market. As awareness and diagnostic capabilities improve, more patients are being identified and treated with immunoglobulin therapies. The chronic nature of these diseases necessitates long-term treatment, leading to sustained demand for SCIg products. Additionally, the growing aging population, which is more susceptible to immune system disorders, further contributes to market expansion.

For instance, Grifols’ Xembify allows infusion at 35 mL/hour per site using up to 6 sites, with post-approval data showing 7 patients sustaining rates ≥ 35 mL/hour/site over three consecutive infusions.

Growing Preference for Home-Based Therapies

Home-based administration of SCIg is becoming increasingly popular due to its convenience, cost-effectiveness, and reduced risk of hospital-acquired infections. Patients prefer self-administration or caregiver-assisted infusions in the comfort of their homes, which enhances treatment compliance and improves quality of life. This shift is strongly supported by healthcare systems and insurance providers aiming to lower hospitalization costs. The growing availability of user-friendly infusion devices further accelerates this homecare trend.

For instance, Octapharma’s cutaquig permits self-administration of 40 mL per site at 25 mL/hour per site, making weekly home treatments easy to manage.

Advancements in Product Formulations and Delivery Systems

Technological advancements in SCIg formulations, including higher concentration products and improved infusion devices, are enhancing the treatment experience for patients. New delivery systems enable faster infusions, smaller infusion volumes, and less frequent dosing, making the therapy more manageable and comfortable. These innovations significantly improve patient adherence and broaden the scope of SCIg applications, driving the market forward. Additionally, ongoing research to develop next-generation immunoglobulin products is expected to further boost market growth.

Key Trends & Opportunities

Expansion in Emerging Markets

The SCIg market is witnessing significant growth opportunities in emerging markets due to increasing healthcare expenditure, improving diagnostic infrastructure, and rising awareness of immunodeficiency diseases. Countries in Asia-Pacific and Latin America are gradually expanding their immunoglobulin therapy coverage, creating new demand for SCIg products. Additionally, regulatory support and local manufacturing initiatives in these regions are expected to facilitate market entry and expansion for global and regional players.

For instance, CSL Behring opened its Broadmeadows plasma fractionation facility in Australia with a processing capacity of 9.2 million liters of plasma per year, boosting local supply and paving the way for enhanced SCIg product availability in Asia-Pacific regions

Increasing Adoption of High-Concentration Products

The demand for high-concentration SCIg products, particularly the 20% segment, is rising as patients and healthcare providers seek to reduce infusion time and volume. High-concentration formulations offer substantial advantages in terms of administration efficiency and patient comfort, making them the preferred choice for long-term therapies. This trend is creating opportunities for manufacturers to develop advanced products with optimized dosing schedules, further expanding their competitive edge in the market.

For instance, Octapharma’s cutaquig underwent a Phase III study where infusion volumes reached a maximum of 108 mL per site, and flow rates peaked at 67.5 mL/hour per site both well above standard dosing parameters demonstrating its potential to streamline therapy regimens.

Key Challenges

High Treatment Costs

The cost of SCIg therapies remains a major barrier, particularly in developing countries with limited reimbursement coverage. The high price of immunoglobulin products and associated delivery devices can restrict patient access, especially in regions where out-of-pocket healthcare spending is significant. Despite their clinical benefits, the affordability of SCIg therapies continues to challenge market penetration and broader adoption.

Supply Chain and Manufacturing Constraints

The SCIg market is highly dependent on plasma collection, which is a time-consuming and resource-intensive process. Fluctuations in plasma supply and stringent regulatory requirements for plasma-derived products can lead to supply shortages and impact product availability. Additionally, the complex manufacturing processes and quality control standards involved in SCIg production pose ongoing operational challenges for market players.

Potential Side Effects and Product Limitations

While SCIg therapies are generally well-tolerated, some patients experience local site reactions, such as swelling, redness, and discomfort, which can affect treatment adherence. In rare cases, systemic side effects may also occur. These concerns, combined with the need for patient education on proper administration techniques, can limit the adoption of SCIg therapies, particularly among newly diagnosed patients or those transitioning from intravenous immunoglobulin (IVIg) treatments.

Regional Analysis

North America

North America held the largest share of the Subcutaneous Immunoglobulin (SCIg) market in 2024, accounting for approximately 48% of the global market, growing from USD 1,855.6 million in 2018 to USD 2,688.0 million in 2024. It is projected to reach USD 4,584.3 million by 2032, advancing at a CAGR of 8.3%. The region’s growth is driven by a well-established healthcare system, rising prevalence of immunodeficiency disorders, and increasing adoption of homecare therapies. High awareness levels and favorable reimbursement policies continue to support North America’s dominant position in the global SCIg market.

Europe

Europe captured around 30% of the global SCIg market share in 2024, with market size increasing from USD 999.2 million in 2018 to USD 1,680.0 million in 2024. The market is expected to reach USD 3,438.2 million by 2032, growing at a CAGR of 8.6%. Factors such as improved access to immunoglobulin therapies, increasing government support, and rising adoption of high-concentration SCIg products are driving growth in this region. Additionally, Europe benefits from strong clinical research infrastructure and expanding home-based healthcare services, further contributing to market development.

Asia Pacific

Asia Pacific is emerging as the fastest-growing region in the SCIg market, holding about 12% market share in 2024. The market expanded from USD 371.1 million in 2018 to USD 672.0 million in 2024, and is projected to reach USD 1,680.9 million by 2032 at a robust CAGR of 10.8%. Rapid healthcare advancements, growing awareness of immunodeficiency treatments, and rising healthcare spending in countries like China, Japan, and India are propelling regional growth. The increasing preference for home-based therapies and expanding diagnostic capabilities are further enhancing the region’s market potential.

Latin America

Latin America accounted for approximately 3% of the global SCIg market in 2024, growing from USD 89.2 million in 2018 to USD 168.0 million in 2024, with the market expected to reach USD 414.8 million by 2032 at a CAGR of 6.8%. Market growth is supported by improving healthcare infrastructure, rising patient awareness, and gradual expansion of immunoglobulin therapy coverage across key countries. However, challenges such as limited reimbursement and affordability issues continue to restrain faster growth in this region despite increasing demand.

Middle East

The Middle East captured around 3% of the global SCIg market in 2024, increasing from USD 178.4 million in 2018 to USD 252.0 million in 2024, and is expected to reach USD 513.0 million by 2032 at a healthy CAGR of 9.1%. Growth in the region is driven by rising investments in healthcare infrastructure, increasing diagnosis rates of immunodeficiency diseases, and growing acceptance of homecare treatment models. Regional healthcare reforms and greater access to advanced therapies are contributing to the steady expansion of the SCIg market in the Middle East.

Africa

Africa held approximately 2% of the global SCIg market share in 2024, with the market size rising from USD 74.9 million in 2018 to USD 140.0 million in 2024. It is projected to reach USD 283.8 million by 2032, growing at a CAGR of 7.9%. The market is gradually developing, supported by improving healthcare accessibility, growing disease awareness, and international health initiatives. However, limited infrastructure, low diagnosis rates, and cost barriers remain key challenges that may restrict faster adoption, although the region presents long-term growth opportunities as healthcare systems evolve.

Market Segmentations:

By Concentration

10%
16.5%
20%
Others

By Application

Primary Immunodeficiency Diseases (PID)
Secondary Immunodeficiency Diseases (SID)
Neurological Disorders (e.g., CIDP)
Others

By End-User

Hospitals
Homecare Settings
Clinics / Specialty Clinics

By Geography

North America
- U.S.
- Canada
- Mexico
Europe
- Germany
- France
- U.K.
- Italy
- Spain
- Rest of Europe
Asia Pacific
- China
- Japan
- India
- South Korea
- South-east Asia
- Rest of Asia Pacific
Latin America
- Brazil
- Argentina
- Rest of Latin America
Middle East & Africa
- GCC Countries
- South Africa
- Rest of the Middle East and Africa

Competitive Landscape

The Subcutaneous Immunoglobulin (SCIg) market is highly competitive and dominated by several key global players, including CSL Behring, Takeda Pharmaceutical Company Limited, Grifols, S.A., and Octapharma AG. These companies maintain a strong market presence through extensive product portfolios, advanced manufacturing capabilities, and robust distribution networks. The competitive landscape is characterized by continuous product innovation, strategic collaborations, and mergers and acquisitions aimed at expanding market reach and enhancing therapeutic offerings. Companies are focusing on developing high-concentration formulations and user-friendly infusion devices to strengthen their positions and meet growing patient demand for convenient home-based therapies. Emerging players such as Bharat Serums and Vaccines Ltd (BSV) and ADMA Biologics are also gaining ground, particularly in regional markets, by offering cost-effective solutions. Additionally, investments in plasma collection facilities and supply chain resilience remain central to the competitive strategies of major manufacturers. The market is witnessing dynamic competition driven by technological advancements and expanding global healthcare access.

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Customize Now

Key Player Analysis

CSL Behring
Takeda Pharmaceutical Company Limited
Grifols, S.A.
Octapharma AG
Kedrion Biopharma
Bio Products Laboratory (BPL)
Biotest AG
LFB Group
Sanquin
Green Cross Corporation
ADMA Biologics
China Biologic Products Holdings, Inc.
Emergent BioSolutions
Bharat Serums and Vaccines Ltd (BSV)

Recent Developments

In March 2025, Grifols announced positive results from a Phase 2/3 trial showing the efficacy of immunoglobulin therapy in post-polio patients, further supporting the clinical utility of their SCIg products.
In 2024, Takeda prioritized expanding its research and development (R&D) pipeline, particularly in immunoglobulin formulations, through strategic acquisitions. This focus aimed to strengthen Takeda’s market share in plasma-derived therapies and other key areas.
In September 2023, Kedrion Biopharma opened a new plasma collection center in the U.S. to enhance its plasma supply for producing therapies like SCIg and other plasma-derived treatments. This expansion aimed to secure a greater quantity of high-quality plasma, crucial for developing life-saving therapies for rare and debilitating conditions.
In July 2023, CSL Behring announced the launch of Hizentra (SCIg) in Japan, marking a significant expansion of their presence in the Asia-Pacific region and offering a convenient subcutaneous immunoglobulin treatment option for patients with primary immunodeficiency disorders (PIDs) in the country.

Market Concentration & Characteristics

The Subcutaneous Immunoglobulin (SCIg) Market displays a moderately consolidated structure, with a few key players controlling a significant portion of global sales. It is characterized by high entry barriers due to stringent regulatory requirements, complex plasma collection processes, and the need for advanced manufacturing capabilities. The market focuses on high-quality, patient-centric therapies with an increasing demand for self-administration solutions. Companies invest in the development of high-concentration products and user-friendly infusion devices to meet evolving patient needs. Homecare settings continue to gain popularity, driving product innovation toward faster, less frequent infusions. The market shows strong brand loyalty, as patients and healthcare providers prefer well-established, proven therapies. It faces supply limitations due to plasma dependency, which can restrict rapid capacity expansion. North America remains the leading region, driven by superior healthcare infrastructure and widespread homecare adoption, while Asia Pacific shows rapid growth potential. Competitive intensity remains high, supported by continuous product development and strategic partnerships.

Report Coverage

The research report offers an in-depth analysis based on Concentration, Application, End-User and Geography. It details leading market players, providing an overview of their business, product offerings, investments, revenue streams, and key applications. Additionally, the report includes insights into the competitive environment, SWOT analysis, current market trends, as well as the primary drivers and constraints. Furthermore, it discusses various factors that have driven market expansion in recent years. The report also explores market dynamics, regulatory scenarios, and technological advancements that are shaping the industry. It assesses the impact of external factors and global economic changes on market growth. Lastly, it provides strategic recommendations for new entrants and established companies to navigate the complexities of the market.

Future Outlook

The demand for Subcutaneous Immunoglobulin (SCIg) therapies will continue to grow due to rising immunodeficiency cases worldwide.
Home-based SCIg treatments will become more popular, supported by patient preference and healthcare cost reduction.
High-concentration SCIg products will see increased adoption for their efficiency and reduced infusion times.
Technological advancements in infusion devices will improve patient convenience and therapy adherence.
Plasma supply challenges may continue to impact production capacity and market expansion.
Key companies will focus on strategic partnerships and regional expansion to strengthen their market positions.
Asia Pacific will experience the fastest market growth due to improving healthcare infrastructure and rising disease awareness.
The market will see increased competition from emerging regional players offering cost-effective solutions.
Healthcare policies and reimbursement improvements will support broader patient access to SCIg therapies.
Continued focus on product innovation will shape future growth and create new opportunities for manufacturers.

CHAPTER NO. 1 : GENESIS OF THE MARKET

1.1 Market Prelude – Introduction & Scope

1.2 The Big Picture – Objectives & Vision

1.3 Strategic Edge – Unique Value Proposition

1.4 Stakeholder Compass – Key Beneficiaries

CHAPTER NO. 2 : EXECUTIVE LENS

2.1 Pulse of the Industry – Market Snapshot

2.2 Growth Arc – Revenue Projections (USD Million)

2.3. Premium Insights – Based on Primary Interviews

CHAPTER NO. 3 : SUBCUTANEOUS IMMUNOGLOBULIN (SCLG) MARKET FORCES & INDUSTRY PULSE

3.1 Foundations of Change – Market Overview
3.2 Catalysts of Expansion – Key Market Drivers
3.2.1 Momentum Boosters – Growth Triggers
3.2.2 Innovation Fuel – Disruptive Technologies
3.3 Headwinds & Crosswinds – Market Restraints
3.3.1 Regulatory Tides – Compliance Challenges
3.3.2 Economic Frictions – Inflationary Pressures
3.4 Untapped Horizons – Growth Potential & Opportunities
3.5 Strategic Navigation – Industry Frameworks
3.5.1 Market Equilibrium – Porter’s Five Forces
3.5.2 Ecosystem Dynamics – Value Chain Analysis
3.5.3 Macro Forces – PESTEL Breakdown

3.6 Price Trend Analysis

3.6.1 Regional Price Trend
3.6.2 Price Trend by product

CHAPTER NO. 4 : KEY INVESTMENT EPICENTER

4.1 Regional Goldmines – High-Growth Geographies

4.2 Product Frontiers – Lucrative Product Categories

4.3 Application Sweet Spots – Emerging Demand Segments

CHAPTER NO. 5: REVENUE TRAJECTORY & WEALTH MAPPING

5.1 Momentum Metrics – Forecast & Growth Curves

5.2 Regional Revenue Footprint – Market Share Insights

5.3 Segmental Wealth Flow – Concentration & Application Revenue

CHAPTER NO. 6 : TRADE & COMMERCE ANALYSIS

6.1. Import Analysis by Region

6.1.1. Global Subcutaneous Immunoglobulin (SClg) Market Import Volume By Region

6.2. Export Analysis by Region

6.2.1. Global Subcutaneous Immunoglobulin (SClg) Market Export Volume By Region

CHAPTER NO. 7 : COMPETITION ANALYSIS

7.1. Company Market Share Analysis

7.1.1. Global Subcutaneous Immunoglobulin (SClg) Market: Company Market Share

7.1. Global Subcutaneous Immunoglobulin (SClg) Market Company Volume Market Share

7.2. Global Subcutaneous Immunoglobulin (SClg) Market Company Revenue Market Share

7.3. Strategic Developments

7.3.1. Acquisitions & Mergers

7.3.2. New Product Launch

7.3.3. Regional Expansion

7.4. Competitive Dashboard

7.5. Company Assessment Metrics, 2024

CHAPTER NO. 8 : SUBCUTANEOUS IMMUNOGLOBULIN (SCLG) MARKET – BY CONCENTRATION SEGMENT ANALYSIS

8.1. Subcutaneous Immunoglobulin (SClg) Market Overview by Concentration Segment

8.1.1. Subcutaneous Immunoglobulin (SClg) Market Volume Share By Concentration

8.1.2. Subcutaneous Immunoglobulin (SClg) Market Revenue Share By Concentration

8.2. 10%

8.3. 16.5%

8.4. 20%

8.5. Others

CHAPTER NO. 9 : SUBCUTANEOUS IMMUNOGLOBULIN (SCLG) MARKET – BY APPLICATION SEGMENT ANALYSIS

9.1. Subcutaneous Immunoglobulin (SClg) Market Overview by Application Segment

9.1.1. Subcutaneous Immunoglobulin (SClg) Market Volume Share By Application

9.1.2. Subcutaneous Immunoglobulin (SClg) Market Revenue Share By Application

9.2. Primary Immunodeficiency Diseases (PID)

9.3. Secondary Immunodeficiency Diseases (SID)

9.4. Neurological Disorders (e.g., CIDP)

9.5. Others

CHAPTER NO. 10 : SUBCUTANEOUS IMMUNOGLOBULIN (SCLG) MARKET – BY END-USER SEGMENT ANALYSIS

10.1. Subcutaneous Immunoglobulin (SClg) Market Overview by End-user Segment

10.1.1. Subcutaneous Immunoglobulin (SClg) Market Volume Share By End-user

10.1.2. Subcutaneous Immunoglobulin (SClg) Market Revenue Share By End-user

10.2. Hospitals

10.3. Homecare Settings

10.4. Clinics / Specialty Clinics

CHAPTER NO. 11 : SUBCUTANEOUS IMMUNOGLOBULIN (SCLG) MARKET – REGIONAL ANALYSIS

11.1. Subcutaneous Immunoglobulin (SClg) Market Overview by Region Segment

11.1.1. Global Subcutaneous Immunoglobulin (SClg) Market Volume Share By Region

11.1.2. Global Subcutaneous Immunoglobulin (SClg) Market Revenue Share By Region

11.1.3. Regions

11.1.4. Global Subcutaneous Immunoglobulin (SClg) Market Volume By Region

11.1.5. Global Subcutaneous Immunoglobulin (SClg) Market Revenue By Region

11.1.6. Concentration

11.1.7. Global Subcutaneous Immunoglobulin (SClg) Market Volume By Concentration

11.1.8. Global Subcutaneous Immunoglobulin (SClg) Market Revenue By Concentration

11.1.9. Application

11.1.10. Global Subcutaneous Immunoglobulin (SClg) Market Volume By Application

11.1.11. Global Subcutaneous Immunoglobulin (SClg) Market Revenue By Application

11.1.12. End-user

11.1.13. Global Subcutaneous Immunoglobulin (SClg) Market Volume By End-user

11.1.14. Global Subcutaneous Immunoglobulin (SClg) Market Revenue By End-user

CHAPTER NO. 12 : NORTH AMERICA SUBCUTANEOUS IMMUNOGLOBULIN (SCLG) MARKET – COUNTRY ANALYSIS

12.1. North America Subcutaneous Immunoglobulin (SClg) Market Overview by Country Segment

12.1.1. North America Subcutaneous Immunoglobulin (SClg) Market Volume Share By Region

12.1.2. North America Subcutaneous Immunoglobulin (SClg) Market Revenue Share By Region

12.2. North America

12.2.1. North America Subcutaneous Immunoglobulin (SClg) Market Volume By Country

12.2.2. North America Subcutaneous Immunoglobulin (SClg) Market Revenue By Country

12.2.3. Concentration

12.2.4. North America Subcutaneous Immunoglobulin (SClg) Market Volume By Concentration

12.2.5. North America Subcutaneous Immunoglobulin (SClg) Market Revenue By Concentration

12.2.6. Application

12.2.7. North America Subcutaneous Immunoglobulin (SClg) Market Volume By Application

12.2.8. North America Subcutaneous Immunoglobulin (SClg) Market Revenue By Application

12.2.9. End-user

12.2.10. North America Subcutaneous Immunoglobulin (SClg) Market Volume By End-user

12.2.11. North America Subcutaneous Immunoglobulin (SClg) Market Revenue By End-user

12.3. U.S.

12.4. Canada

12.5. Mexico

CHAPTER NO. 13 : EUROPE SUBCUTANEOUS IMMUNOGLOBULIN (SCLG) MARKET – COUNTRY ANALYSIS

13.1. Europe Subcutaneous Immunoglobulin (SClg) Market Overview by Country Segment

13.1.1. Europe Subcutaneous Immunoglobulin (SClg) Market Volume Share By Region

13.1.2. Europe Subcutaneous Immunoglobulin (SClg) Market Revenue Share By Region

13.2. Europe

13.2.1. Europe Subcutaneous Immunoglobulin (SClg) Market Volume By Country

13.2.2. Europe Subcutaneous Immunoglobulin (SClg) Market Revenue By Country

13.2.3. Concentration

13.2.4. Europe Subcutaneous Immunoglobulin (SClg) Market Volume By Concentration

13.2.5. Europe Subcutaneous Immunoglobulin (SClg) Market Revenue By Concentration

13.2.6. Application

13.2.7. Europe Subcutaneous Immunoglobulin (SClg) Market Volume By Application

13.2.8. Europe Subcutaneous Immunoglobulin (SClg) Market Revenue By Application

13.2.9. End-user

13.2.10. Europe Subcutaneous Immunoglobulin (SClg) Market Volume By End-user

13.2.11. Europe Subcutaneous Immunoglobulin (SClg) Market Revenue By End-user

13.3. UK

13.4. France

13.5. Germany

13.6. Italy

13.7. Spain

13.8. Russia

13.9. Rest of Europe

CHAPTER NO. 14 : ASIA PACIFIC SUBCUTANEOUS IMMUNOGLOBULIN (SCLG) MARKET – COUNTRY ANALYSIS

14.1. Asia Pacific Subcutaneous Immunoglobulin (SClg) Market Overview by Country Segment

14.1.1. Asia Pacific Subcutaneous Immunoglobulin (SClg) Market Volume Share By Region

14.1.2. Asia Pacific Subcutaneous Immunoglobulin (SClg) Market Revenue Share By Region

14.2. Asia Pacific

14.2.1. Asia Pacific Subcutaneous Immunoglobulin (SClg) Market Volume By Country

14.2.2. Asia Pacific Subcutaneous Immunoglobulin (SClg) Market Revenue By Country

14.2.3. Concentration

14.2.4. Asia Pacific Subcutaneous Immunoglobulin (SClg) Market Volume By Concentration

14.2.5. Asia Pacific Subcutaneous Immunoglobulin (SClg) Market Revenue By Concentration

14.2.6. Application

14.2.7. Asia Pacific Subcutaneous Immunoglobulin (SClg) Market Volume By Application

14.2.8. Asia Pacific Subcutaneous Immunoglobulin (SClg) Market Revenue By Application

14.2.9. End-user

14.2.10. Asia Pacific Subcutaneous Immunoglobulin (SClg) Market Volume By End-user

14.2.11. Asia Pacific Subcutaneous Immunoglobulin (SClg) Market Revenue By End-user

14.3. China

14.4. Japan

14.5. South Korea

14.6. India

14.7. Australia

14.8. Southeast Asia

14.9. Rest of Asia Pacific

CHAPTER NO. 15 : LATIN AMERICA SUBCUTANEOUS IMMUNOGLOBULIN (SCLG) MARKET – COUNTRY ANALYSIS

15.1. Latin America Subcutaneous Immunoglobulin (SClg) Market Overview by Country Segment

15.1.1. Latin America Subcutaneous Immunoglobulin (SClg) Market Volume Share By Region

15.1.2. Latin America Subcutaneous Immunoglobulin (SClg) Market Revenue Share By Region

15.2. Latin America

15.2.1. Latin America Subcutaneous Immunoglobulin (SClg) Market Volume By Country

15.2.2. Latin America Subcutaneous Immunoglobulin (SClg) Market Revenue By Country

15.2.3. Concentration

15.2.4. Latin America Subcutaneous Immunoglobulin (SClg) Market Volume By Concentration

15.2.5. Latin America Subcutaneous Immunoglobulin (SClg) Market Revenue By Concentration

15.2.6. Application

15.2.7. Latin America Subcutaneous Immunoglobulin (SClg) Market Volume By Application

15.2.8. Latin America Subcutaneous Immunoglobulin (SClg) Market Revenue By Application

15.2.9. End-user

15.2.10. Latin America Subcutaneous Immunoglobulin (SClg) Market Volume By End-user

15.2.11. Latin America Subcutaneous Immunoglobulin (SClg) Market Revenue By End-user

15.3. Brazil

15.4. Argentina

15.5. Rest of Latin America

CHAPTER NO. 16 : MIDDLE EAST SUBCUTANEOUS IMMUNOGLOBULIN (SCLG) MARKET – COUNTRY ANALYSIS

16.1. Middle East Subcutaneous Immunoglobulin (SClg) Market Overview by Country Segment

16.1.1. Middle East Subcutaneous Immunoglobulin (SClg) Market Volume Share By Region

16.1.2. Middle East Subcutaneous Immunoglobulin (SClg) Market Revenue Share By Region

16.2. Middle East

16.2.1. Middle East Subcutaneous Immunoglobulin (SClg) Market Volume By Country

16.2.2. Middle East Subcutaneous Immunoglobulin (SClg) Market Revenue By Country

16.2.3. Concentration

16.2.4. Middle East Subcutaneous Immunoglobulin (SClg) Market Volume By Concentration

16.2.5. Middle East Subcutaneous Immunoglobulin (SClg) Market Revenue By Concentration

16.2.6. Application

16.2.7. Middle East Subcutaneous Immunoglobulin (SClg) Market Volume By Application

16.2.8. Middle East Subcutaneous Immunoglobulin (SClg) Market Revenue By Application

16.2.9. End-user

16.2.10. Middle East Subcutaneous Immunoglobulin (SClg) Market Volume By End-user

16.2.11. Middle East Subcutaneous Immunoglobulin (SClg) Market Revenue By End-user

16.3. GCC Countries

16.4. Israel

16.5. Turkey

16.6. Rest of Middle East

CHAPTER NO. 17 : AFRICA SUBCUTANEOUS IMMUNOGLOBULIN (SCLG) MARKET – COUNTRY ANALYSIS

17.1. Africa Subcutaneous Immunoglobulin (SClg) Market Overview by Country Segment

17.1.1. Africa Subcutaneous Immunoglobulin (SClg) Market Volume Share By Region

17.1.2. Africa Subcutaneous Immunoglobulin (SClg) Market Revenue Share By Region

17.2. Africa

17.2.1. Africa Subcutaneous Immunoglobulin (SClg) Market Volume By Country

17.2.2. Africa Subcutaneous Immunoglobulin (SClg) Market Revenue By Country

17.2.3. Concentration

17.2.4. Africa Subcutaneous Immunoglobulin (SClg) Market Volume By Concentration

17.2.5. Africa Subcutaneous Immunoglobulin (SClg) Market Revenue By Concentration

17.2.6. Application

17.2.7. Africa Subcutaneous Immunoglobulin (SClg) Market Volume By Application

17.2.8. Africa Subcutaneous Immunoglobulin (SClg) Market Revenue By Application

17.2.9. End-user

17.2.10. Africa Subcutaneous Immunoglobulin (SClg) Market Volume By End-user

17.2.11. Africa Subcutaneous Immunoglobulin (SClg) Market Revenue By End-user

17.3. South Africa

17.4. Egypt

17.5. Rest of Africa

CHAPTER NO. 18 : COMPANY PROFILES

18.1. CSL Behring

18.1.1. Company Overview

18.1.2. Product Portfolio

18.1.3. Financial Overview

18.1.4. Recent Developments

18.1.5. Growth Strategy

18.1.6. SWOT Analysis

18.2. Takeda Pharmaceutical Company Limited

18.3. Grifols, S.A.

18.4. Octapharma AG

18.5. Kedrion Biopharma

18.6. Bio Products Laboratory (BPL)

18.7. Biotest AG

18.8. LFB Group

18.9. Sanquin

18.10. Green Cross Corporation

18.11. ADMA Biologics.

18.12. China Biologic Products Holdings, Inc.

18.13. Emergent BioSolutions

18.14. Bharat Serums and Vaccines Ltd (BSV)

Ready to Transform Data into Decisions?

Request Your Sample Report and Start Your Journey of Informed Choices

Providing the strategic compass for industry titans.

Request Sample

We prioritize the confidentiality and security of your data. Our promise: your information remains private.

Frequently Asked Questions

What is the current size of the Subcutaneous Immunoglobulin (SCIg) Market?

The Subcutaneous Immunoglobulin (SCIg) market is valued at USD 5,600.0 million in 2024 and is projected to grow steadily.

What are the key segments within the Subcutaneous Immunoglobulin (SCIg) Market?

The market is segmented by Concentration, Application, End-User, and Geography.

What are some challenges faced by the Subcutaneous Immunoglobulin (SCIg) Market?

Key challenges include high treatment costs, plasma supply limitations, and potential side effects.

Who are the major players in the Subcutaneous Immunoglobulin (SCIg) Market?

Major players include CSL Behring, Takeda Pharmaceutical, Grifols, Octapharma, and Bharat Serums and Vaccines Ltd (BSV).

About Author

Shweta Bisht

Healthcare & Biotech Analyst

Shweta is a healthcare and biotech researcher with strong analytical skills in chemical and agri domains.

View Profile

Switzerland Diabetes Drugs Market

Switzerland Diabetes Drugs Market size was valued at USD 411.31 million in 2023 and is anticipated to reach USD 482.00 million by 2032, at a CAGR of 1.38% during the forecast period (2023-2032).

Japan Diabetes Drugs Market

Japan Diabetes Drugs market size was valued at USD 4,844.79 million in 2023 and is anticipated to reach USD 6,874.61 million by 2032, at a CAGR of 3.56% during the forecast period (2023-2032).

Spain Diabetes Drugs Market

Spain Diabetes Drugs market size was valued at USD 1,610.26 million in 2023 and is anticipated to reach USD 1,885.18 million by 2032, at a CAGR of 1.37% during the forecast period (2023-2032).

South Korea Diabetes Drugs Market

South Korea Diabetes Drugs Market size was valued at USD 3,344.06 million in 2023 and is anticipated to reach USD 4,823.91 million by 2032, at a CAGR of 3.75% during the forecast period (2023-2032).

Australia Diabetes Drugs Market

Australia Diabetes Drugs Market size was valued at USD 586.15 million in 2023 and is anticipated to reach USD 826.11 million by 2032, at a CAGR of 3.48% during the forecast period (2023-2032).

Indonesia Diabetes Drugs Market

Indonesia Diabetes Drugs Market size was valued at USD 482.65 million in 2023 and is anticipated to reach USD 631.76 million by 2032, at a CAGR of 2.62% during the forecast period (2023-2032).

South Africa Diabetes Drugs Market

South Africa Diabetes Drugs Market size was valued at USD 330.45 million in 2023 and is anticipated to reach USD 353.64 million by 2032, at a CAGR of 0.31% during the forecast period (2023-2032).

Netherlands Diabetes Drugs Market

Netherlands Diabetes Drugs Market size was valued at USD 738.19 million in 2023 and is anticipated to reach USD 909.62 million by 2032, at a CAGR of 1.95% during the forecast period (2023-2032).

Mexico Diabetes Drugs Market

Mexico Diabetes Drugs Market size was valued at USD 2,017.77 million in 2023 and is anticipated to reach USD 2,458.36 million by 2032, at a CAGR of 1.82% during the forecast period (2023-2032).

Epilepsy Treatment Drugs Market

The Epilepsy Treatment Drugs Market size was valued at USD 11739.4 million in 2024 and is anticipated to reach USD 18291.4 million by 2032, at a CAGR of 5.7% during the forecast period (2024-2032).

Collagen Peptide And Gelatin Market

The Collagen Peptide and Gelatin Market size was valued at USD 1,448.4 million in 2018 to USD 2,417.3 million in 2024 and is anticipated to reach USD 4,738.9 million by 2032, at a CAGR of 8.81% during the forecast period.

Biopharmaceutical Logistics Market

The biopharmaceutical logistics market size was valued at USD 145692.7 million in 2024 and is anticipated to reach USD 254854.5 million by 2032, at a CAGR of 7.24 % during the forecast period (2024-2032).

Telepharmacy Market

The Telepharmacy market is projected to grow from USD 10,735 million in 2024 to an estimated USD 23,011.4 million by 2032, with a compound annual growth rate (CAGR) of 10% from 2024 to 2032.

Telemedicine Market

The Telemedicine market is projected to grow from USD 141,135 million in 2024 to USD 523,000 million by 2032, registering a robust CAGR of 17.79%.

Telemedicine Cart Market

The Telemedicine cart market is projected to grow from USD 1,033 million in 2024 to USD 3,011.43 million by 2032, registering a robust compound annual growth rate (CAGR) of 14.31%.

Acute Myeloid Leukemia Therapeutics Market

The Global Acute Myeloid Leukemia (AML) Therapeutics Market size was valued at USD 1,933.8 million in 2018 to USD 3,349.2 million in 2024 and is anticipated to reach USD 6,823.4 million by 2032, at a CAGR of 9.33% during the forecast period

Acute Coronary Syndrome Therapeutics Market

The acute coronary syndrome therapeutics market is projected to grow from USD 9,715 million in 2024 to USD 16,138.7 million by 2032, registering a compound annual growth rate (CAGR) of 6.55%.

Biosimulation Market

The biosimulation market size was valued at USD 1,503.4 million in 2018, increased to USD 3,793.2 million in 2024, and is anticipated to reach USD 13,653.2 million by 2032, at a CAGR of 17.54% during the forecast period.

Acute Bacterial Skin And Skin Structure Infections Market

The acute bacterial skin and skin structure infections market is projected to grow from USD 11,695 million in 2024 to USD 24,527.4 million by 2032, registering a compound annual growth rate (CAGR) of 9.7%.

Acromegaly Treatment Market

The Acromegaly Treatment Market size was valued at USD 1550 million in 2024 and is anticipated to reach USD 2489.1 million by 2032, at a CAGR of 8.9% during the forecast period (2024-2032).

Organoids in Drug Discovery Market

The Organoids in Drug Discovery Market size was valued at USD 677.4 million in 2018 to USD 1,709.2 million in 2024 and is anticipated to reach USD 6,152.1 million by 2032, at a CAGR of 17.54% during the forecast period.

Purchase Options

Single User

$4699

Multi User

$5699

Custom Report

$12699

Let us help you

WILLIAM, North America

+1 304 308 1216

KEITH PHILLIPS, Europe

+44 7809 866 263

LEE VALLANCE, Asia Pacific

+64 22 017 0275

KIERAN JAMESON, Australia

+61 4192 46279

Report delivery within 24 to 48 hours

What people say?

Thank you for the data! The numbers are exactly what we asked for and what we need to build our business case.

Materials Scientist
(privacy requested)

The report was an excellent overview of the Industrial Burners market. This report does a great job of breaking everything down into manageable chunks.

Imre Hof
Management Assistant, Bekaert

Market Overview

Market Insights

Access crucial information at unmatched prices!

Market Segmentation Analysis:

Market Overview

Increasing Prevalence of Immunodeficiency Disorders

Growing Preference for Home-Based Therapies

Advancements in Product Formulations and Delivery Systems

Key Trends & Opportunities

Expansion in Emerging Markets

Increasing Adoption of High-Concentration Products

Key Challenges

Supply Chain and Manufacturing Constraints

Potential Side Effects and Product Limitations

Regional Analysis

Market Segmentations:

Competitive Landscape

Shape Your Report to Specific Countries or Regions & Enjoy 30% Off!

Key Player Analysis

Recent Developments

Market Concentration & Characteristics

Report Coverage

Future Outlook

Ready to Transform Data into Decisions?

Providing the strategic compass for industry titans.

Request Sample

About Author

Shweta Bisht

Related Reports By Keyword

Related Reports

Purchase Options

Let us help you

What people say?

Trusted By